Results 41 to 50 of about 41,221 (142)

Systematic Review of Neovascular Age-Related Macular Degeneration Disease Activity Criteria Use to Shorten, Maintain or Extend Treatment Intervals with Anti-VEGF in Clinical Trials: Implications for Clinical Practice

Ophthalmology and Therapy, 2023
Introduction Clinical trials in neovascular age-related macular degeneration (nAMD) using anti-vascular endothelial growth factor (ant-VEGF) injections use disease activity (DA) criteria to shorten, maintain or increase the interval between injections ...
Praveen J. Patel, Pablo Villavicencio, Daren Hanumunthadu   +2 more
doaj   +1 more source

Case Report: Extending dosing intervals of biologics in adults severe asthma: a case series

Frontiers in Allergy
BackgroundBiological therapies have improved the control of severe asthma. However, biological therapies are expensive. Therefore, the cost-effective use of these medications after achieving improved disease control warrants consideration.MethodsThis ...
Tomoya Harada, Miyu Nishigami, Hiroyuki Tanaka, Hiroyuki Tanaka, Genki Inui, Hiroki Ishikawa, Hiroki Kohno, Yoshihiro Funaki, Tomohiro Sakamoto, Miki Takata, Ryota Okazaki, Masato Morita, Shin Kitatani, Akira Yamasaki   +13 more
doaj   +1 more source

Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients

CPT: Pharmacometrics & Systems Pharmacology, 2023
Atezolizumab is an anti‐PDL1 approved for treating lung cancer. A threshold of 6 μg/mL in plasma has been associated with target engagement. The extent to which patients could be overexposed with the standard 1200 mg q3w dosing remains unknown.
Sophie Marolleau, Alice Mogenet, Clara Boeri, Mourad Hamimed, Joseph Ciccolini, Laurent Greillier   +5 more
doaj   +1 more source

Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial

BMC Cancer, 2010
Background Chemotherapy-induced anemia (CIA) is responsive to treatment with erythropoiesis-stimulating agents (ESAs) such as darbepoetin alfa. Administration of ESAs on a synchronous schedule with chemotherapy administration could benefit patients by ...
Silberstein Peter, Rearden Timothy, Mirtsching Barry, Burkes Ronald, Schwartzberg Lee, Yee Lorrin, Inamoto Amy, Lillie Tom   +7 more
doaj   +1 more source

Predictive performance of gentamicin dosing nomograms

Drug Design, Development and Therapy, 2014
Jieon Lee,1 Seonghae Yoon,1 Donghoon Shin,1 HyeKyung Han,1 Hyungmi An,1,2 Jongtae Lee,1 Kyoung Soo Lim,3 Kyung-Sang Yu,1 Howard Lee11Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul ...
Lee J, Yoon S, Shin D, Han H, An H, Lee J, Lim KS, Yu KS, Lee H   +8 more
doaj  

Impact of prednisolone tapering and extended dupilumab dosing intervals on comorbid asthma in patients with chronic rhinosinusitis with nasal polyps

Journal of Allergy and Clinical Immunology: Global
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently coexists with asthma and involves type 2 inflammation. Dupilumab enables prednisolone (PSL) tapering and extended dosing intervals in CRSwNP, but the impact on comorbid asthma is ...
Shunsuke Minagawa, MD, PhD, Masahiro Yoshida, MD, PhD, Daiki Nakashima, MD, Takanori Numata, MD, PhD, Shun Inukai, MD, Tomoya Maruyama, MD, Tetsuya Adachi, MD, PhD, Jun Araya, MD, PhD, Yoshinori Matsuwaki, MD, PhD   +8 more
doaj   +1 more source

Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept

Life
We investigated the factors associated with the success of switching to faricimab for type 1 macular neovascularization (MNV) refractory to intravitreal aflibercept (IVA).
Akira Machida, Akio Oishi, Junichiro Ikeda, Junko Kurihara, Ai Yoneda, Eiko Tsuiki, Yuki Hirata, Ryuya Murakami, Takashi Kitaoka   +8 more
doaj   +1 more source

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

Neurology and Therapy
Introduction Following NOVA (part 1) and the approval of the subcutaneous (SC) route of administration of natalizumab by the European Medicines Agency, an extension phase of the NOVA phase IIIb study (part 2) was initiated to collect patient preference ...
Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky   +15 more
doaj   +1 more source

Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial.

PLoS ONE
PurposeIn patients with diabetic macular edema (DME) from YOSEMITE/RHINE, dual angiopoietin-2/vascular endothelial growth factor-A (VEGF-A) inhibition with faricimab resulted in visual/anatomic improvements with extended dosing.
Takao Hirano, Toshinori Murata, Shintaro Nakao, Masahiko Shimura, Miho Nozaki, Kiyoshi Suzuma, Taiji Nagaoka, Masahiko Sugimoto, Yoshihiro Takamura, Tomoaki Murakami, Keisuke Iwasaki, Jun Tsujimura, Shigeo Yoshida   +12 more
doaj   +1 more source

Treatment Patterns and Characteristics of Patients with Hereditary Angioedema Treated with Lanadelumab: A US Retrospective Chart Review

Drugs - Real World Outcomes
Background and Objective Hereditary angioedema presents as recurrent, unpredictable, and often debilitating attacks of cutaneous/submucosal swelling.
Maureen Watt, Rose Chang, Louise Huafeng Yu, Louise Clear, Maral DerSarkissian   +4 more
doaj   +1 more source